Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has shared an announcement.
Sinopharm Group Co. Ltd. has announced the composition of its board of directors and the roles within its five board committees. The announcement provides details on the leadership structure, which includes a mix of non-executive, executive, and independent non-executive directors, highlighting the company’s governance framework and strategic oversight.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical and healthcare products. The company is registered as a non-Hong Kong entity under the Hong Kong Companies Ordinance.
Average Trading Volume: 5,306,221
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$60.53B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.